Home / Irbesartan and Diuretics / Canada
CA ATC C09DA04 · updated 2 Nov 2026
Irbesartan and Diuretics shortage in Canada
Is there an Irbesartan and Diuretics shortage in Canada?
Yes. As of 2 Nov 2026, 18 Irbesartan and Diuretics products are reported short in Canada, the first since 17 Sep 2018. The company estimate for the return is 18 Dec 2026 (latest 31 Dec 2027). Main reason: manufacturing problem.
Also short in Italy, Spain, Belgium. All countries.
Affected products in Canada
| Country | Product | Company | Since | Expected back | Reason |
|---|---|---|---|---|---|
| CA | AURO-IRBESARTAN HCT (90) | AURO PHARMA INC | 17 Sep 2018 | not given | Manufacturing problem Requirements related to complying with good manufacturing practices |
| CA | AURO-IRBESARTAN HCT (90) | AURO PHARMA INC | 17 Oct 2018 | not given | Manufacturing problem Requirements related to complying with good manufacturing practices |
| CA | AURO-IRBESARTAN HCT (90) | AURO PHARMA INC | 17 Oct 2018 | not given | Manufacturing problem Requirements related to complying with good manufacturing practices |
| CA | JAMP-IRBESARTAN AND HYDROCHLOROTHIAZIDE (100) | JAMP PHARMA CORPORATION | 7 Oct 2019 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CA | JAMP-IRBESARTAN AND HYDROCHLOROTHIAZIDE (100) | JAMP PHARMA CORPORATION | 7 Oct 2019 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CA | JAMP-IRBESARTAN AND HYDROCHLOROTHIAZIDE (100) | JAMP PHARMA CORPORATION | 7 Oct 2019 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CA | JAMP-IRBESARTAN AND HYDROCHLOROTHIAZIDE (28) | JAMP PHARMA CORPORATION | 7 Oct 2019 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CA | JAMP-IRBESARTAN AND HYDROCHLOROTHIAZIDE (28) | JAMP PHARMA CORPORATION | 7 Oct 2019 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CA | JAMP-IRBESARTAN AND HYDROCHLOROTHIAZIDE (28) | JAMP PHARMA CORPORATION | 7 Oct 2019 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CA | JAMP-IRBESARTAN AND HYDROCHLOROTHIAZIDE (100) | JAMP PHARMA CORPORATION | 7 Oct 2019 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CA | PMS-IRBESARTAN-HCTZ (100) | PHARMASCIENCE INC | 14 Nov 2022 | 31 Dec 2027 | Manufacturing problem Disruption of the manufacture of the drug |
| CA | TEVA-IRBESARTAN HCTZ (100) | TEVA CANADA LIMITED | 10 Mar 2024 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CA | IRBESARTAN/HCTZ (100) | SANIS HEALTH INC | 1 Jun 2024 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CA | IRBESARTAN/HCTZ (100) | SANIS HEALTH INC | 7 Oct 2024 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CA | IRBESARTAN/HCTZ (100) | SANIS HEALTH INC | 18 Nov 2024 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CA | PMS-IRBESARTAN-HCTZ (100) | PHARMASCIENCE INC | 21 Jul 2026 | 31 Jan 2027 | Manufacturing problem Disruption of the manufacture of the drug |
| CA | PMS-IRBESARTAN-HCTZ (100) | PHARMASCIENCE INC | 4 Sep 2026 | 3 Mar 2027 | Manufacturing problem Disruption of the manufacture of the drug |
| CA | AVALIDE (90) | SANOFI-AVENTIS CANADA INC | 7 Oct 2026 | 18 Dec 2026 | Other Other (Please describe in comments) |
Source
Health Canada, Health Product Shortages Canada. Official list. Mandatory company reports since 2017: actual and anticipated shortages, plus products about to be discontinued.